JP2015061852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015061852A5 JP2015061852A5 JP2014229970A JP2014229970A JP2015061852A5 JP 2015061852 A5 JP2015061852 A5 JP 2015061852A5 JP 2014229970 A JP2014229970 A JP 2014229970A JP 2014229970 A JP2014229970 A JP 2014229970A JP 2015061852 A5 JP2015061852 A5 JP 2015061852A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- nephropathy
- pharmaceutical composition
- renal
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 208000017169 kidney disease Diseases 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 206010029155 Nephropathy toxic Diseases 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000001434 glomerular Effects 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010069384 Ischaemic nephropathy Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010038468 Renal hypertrophy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000007596 consolidation process Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 210000005086 glomerual capillary Anatomy 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000008627 kidney hypertrophy Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 238000013059 nephrectomy Methods 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17523509P | 2009-05-04 | 2009-05-04 | |
| US61/175,235 | 2009-05-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508861A Division JP2012526052A (ja) | 2009-05-04 | 2010-05-03 | 置換芳香族化合物およびその薬学的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015061852A JP2015061852A (ja) | 2015-04-02 |
| JP2015061852A5 true JP2015061852A5 (https=) | 2015-05-28 |
| JP5815829B2 JP5815829B2 (ja) | 2015-11-17 |
Family
ID=43049874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508861A Ceased JP2012526052A (ja) | 2009-05-04 | 2010-05-03 | 置換芳香族化合物およびその薬学的使用 |
| JP2014229970A Expired - Fee Related JP5815829B2 (ja) | 2009-05-04 | 2014-11-12 | 置換芳香族化合物およびその薬学的使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508861A Ceased JP2012526052A (ja) | 2009-05-04 | 2010-05-03 | 置換芳香族化合物およびその薬学的使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8927765B2 (https=) |
| EP (1) | EP2427416B1 (https=) |
| JP (2) | JP2012526052A (https=) |
| KR (2) | KR20120024696A (https=) |
| CN (1) | CN102438975B (https=) |
| AU (1) | AU2010244930B2 (https=) |
| BR (1) | BRPI1015124B8 (https=) |
| CA (1) | CA2761018C (https=) |
| DK (1) | DK2427416T3 (https=) |
| EA (1) | EA022445B1 (https=) |
| ES (1) | ES2575100T3 (https=) |
| HU (1) | HUE029126T2 (https=) |
| IL (1) | IL216006A (https=) |
| MX (1) | MX2011011757A (https=) |
| MY (1) | MY156780A (https=) |
| NZ (1) | NZ595978A (https=) |
| PL (1) | PL2427416T3 (https=) |
| PT (1) | PT2427416E (https=) |
| SG (1) | SG175855A1 (https=) |
| TW (1) | TWI485134B (https=) |
| WO (1) | WO2010127440A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011011756A (es) * | 2009-05-04 | 2012-01-25 | Prometic Biosciences Inc | Sales de acido 3-pentilfenilacetico y usos farmaceuticos. |
| PT2427416E (pt) | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Compostos aromáticos substituídos e seus usos farmacêuticos |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
| MX365807B (es) * | 2010-10-27 | 2019-06-14 | Prometic Pharma Smt Ltd | Compuestos y composiciones para el tratamiento del cáncer. |
| CA2816094A1 (en) * | 2010-10-27 | 2012-07-26 | Prometic Biosciences Inc. | Compounds and pharmaceutical compositions for uses in diabetes |
| TWI742541B (zh) | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| CA2930584A1 (en) | 2013-11-15 | 2015-05-21 | The Wistar Institute Of Anatomy And Biology | Ebna1 inhibitors and their method of use |
| GB201416017D0 (en) * | 2014-09-10 | 2014-10-22 | New Royal Holloway & Bedford | An Anticonvulsant Compound |
| ES2785317T3 (es) * | 2014-10-10 | 2020-10-06 | Liminal Biosciences Ltd | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis |
| KR20170072352A (ko) * | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
| AU2016262572B2 (en) | 2015-05-14 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | EBNA1 inhibitors and methods using same |
| EP3793546B1 (en) | 2018-05-17 | 2025-11-19 | The Wistar Institute | Ebna1 inhibitor crystalline forms, and methods of preparing and using same |
| CN108997202A (zh) * | 2018-07-10 | 2018-12-14 | 湖南华腾制药有限公司 | 一种（5-三氟甲基-吡啶-2-基）-乙酸盐的制备方法 |
| MA53188A1 (fr) | 2018-10-11 | 2021-12-31 | Basf As | Composés aromatiques et leurs utilisations pharmaceutiques |
| WO2020113340A1 (en) * | 2018-12-05 | 2020-06-11 | Liminal Biosciences Limited | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome |
| EP4051659B1 (en) * | 2019-10-31 | 2026-01-28 | Assia Chemical Industries Ltd. | Solid state forms of fezagepras and process for preparation thereof |
| CN115974773B (zh) * | 2022-12-30 | 2024-07-02 | 广东省科学院生物与医学工程研究所 | 甘蔗内生真菌所产的化合物及其在抑菌和抗氧化中的应用 |
| WO2024217515A1 (zh) * | 2023-04-19 | 2024-10-24 | 上海复宏汉霖生物技术股份有限公司 | 一种杂环取代的芳香化合物、其制备方法及用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2489348A (en) * | 1947-01-15 | 1949-11-29 | Hoffmann La Roche | Production of arylacetic acids and amides |
| US2618645A (en) * | 1948-11-12 | 1952-11-18 | Bowles Albert Frank | Organic mercurials |
| GB971700A (en) * | 1961-02-02 | 1964-09-30 | Boots Pure Drug Co Ltd | Anti-Inflammatory Agents |
| US4021478A (en) * | 1972-07-13 | 1977-05-03 | The Upjohn Company | Preparation of carboxylic acids from glycidonitriles with ionic lewis acids |
| GB1465219A (en) * | 1975-02-25 | 1977-02-23 | Juste Sa | Process for the preparation of a phenyl alkonoic acid and its salts |
| JPS52107837A (en) * | 1976-03-05 | 1977-09-09 | Ricoh Co Ltd | Wet type electrostatic development material |
| NL7709681A (nl) * | 1976-09-08 | 1978-03-10 | Sandoz Ag | Werkwijzen voor het bereiden en toepassen van fenylazijnzuurderivaten. |
| US4264582A (en) * | 1978-07-31 | 1981-04-28 | The Procter & Gamble Company | Isobutylphenylacetate anti-inflammatory composition |
| JPS5656899A (en) * | 1979-10-17 | 1981-05-19 | Pilot Pen Co Ltd:The | Recording material |
| FR2497524B1 (https=) | 1981-01-07 | 1985-12-13 | Rhone Poulenc Spec Chim | |
| JPS5855469A (ja) * | 1981-09-25 | 1983-04-01 | Sumitomo Chem Co Ltd | イソシアヌル酸誘導体、その製造方法およびこれを有効成分とする有機物質用安定剤 |
| US4482439A (en) * | 1984-04-05 | 1984-11-13 | Reilly Tar & Chemical Corp. | Electrochemical oxidation of pyridine bases |
| EP0268907A3 (en) | 1986-11-19 | 1990-03-21 | Carl Richard Thornfeldt | Treatment of disease conditions relating to hyperactive organelles |
| JPS63236519A (ja) * | 1987-03-24 | 1988-10-03 | Ube Ind Ltd | 有害廃ガスの処理方法 |
| CA2004028C (en) * | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
| IE70430B1 (en) * | 1990-02-13 | 1996-11-27 | Lonza Ag | Microbiological oxidation of methyl groups in heterocyclic compounds |
| US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| GB9200689D0 (en) * | 1992-01-14 | 1992-03-11 | Rhone Poulenc Agriculture | New compositions of matter |
| US5366996A (en) | 1992-12-07 | 1994-11-22 | Elford Howard L | Method of treating hemoglobinopathies |
| IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
| US20060074063A1 (en) | 1995-12-29 | 2006-04-06 | Fernandez-Pol Jose A | Pharmacological agent and method of treatment |
| US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
| JPH11343283A (ja) * | 1998-05-29 | 1999-12-14 | Koei Chem Co Ltd | ピリジンカルボン酸の製造法 |
| EP1200460A1 (en) * | 1999-07-15 | 2002-05-02 | Eli Lilly And Company | Pseudomycin n-acyl side-chain analogs |
| WO2001074487A1 (en) * | 2000-04-04 | 2001-10-11 | Daicel Chemical Industries, Ltd. | Method of separating imide compound |
| ITMI20012434A1 (it) * | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| FR2849849B1 (fr) * | 2003-01-13 | 2006-08-04 | Merck Sante Sas | Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies |
| BRPI0616463A2 (pt) * | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| US20100010002A1 (en) | 2006-09-01 | 2010-01-14 | Piramal Life Sciences Limited | Anticancer use of caffeic acid and its derivatives |
| ES2400163T3 (es) * | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Derivados de piridil-3-ilo como agentes de inmunomodulación |
| US8598208B2 (en) * | 2007-08-17 | 2013-12-03 | Actelion Pharmaceuticals Ltd. | Pyridine derivatives as S1P1/EDG1 receptor modulators |
| ZA200801666B (en) * | 2007-09-29 | 2009-01-28 | Merck & Co Inc | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| WO2009055932A1 (en) | 2007-11-02 | 2009-05-07 | Prometic Biosciences Inc. | Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis |
| CN101878028A (zh) | 2007-11-02 | 2010-11-03 | 普罗米蒂克生物科学公司 | 作为肾保护剂的中链长度脂肪酸和甘油酯 |
| NZ586249A (en) | 2007-12-19 | 2012-05-25 | Prometic Biosciences Inc | A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer |
| PT2427416E (pt) | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Compostos aromáticos substituídos e seus usos farmacêuticos |
| MX2011011756A (es) * | 2009-05-04 | 2012-01-25 | Prometic Biosciences Inc | Sales de acido 3-pentilfenilacetico y usos farmaceuticos. |
-
2010
- 2010-05-03 PT PT107719338T patent/PT2427416E/pt unknown
- 2010-05-03 CA CA2761018A patent/CA2761018C/en active Active
- 2010-05-03 TW TW099114044A patent/TWI485134B/zh not_active IP Right Cessation
- 2010-05-03 HU HUE10771933A patent/HUE029126T2/en unknown
- 2010-05-03 PL PL10771933.8T patent/PL2427416T3/pl unknown
- 2010-05-03 KR KR1020117028778A patent/KR20120024696A/ko not_active Ceased
- 2010-05-03 KR KR1020187001772A patent/KR101923354B1/ko not_active Expired - Fee Related
- 2010-05-03 EA EA201171350A patent/EA022445B1/ru not_active IP Right Cessation
- 2010-05-03 WO PCT/CA2010/000677 patent/WO2010127440A1/en not_active Ceased
- 2010-05-03 MY MYPI2011004980A patent/MY156780A/en unknown
- 2010-05-03 CN CN201080023204.7A patent/CN102438975B/zh not_active Expired - Fee Related
- 2010-05-03 DK DK10771933.8T patent/DK2427416T3/en active
- 2010-05-03 BR BRPI1015124A patent/BRPI1015124B8/pt not_active IP Right Cessation
- 2010-05-03 NZ NZ595978A patent/NZ595978A/xx not_active IP Right Cessation
- 2010-05-03 AU AU2010244930A patent/AU2010244930B2/en not_active Ceased
- 2010-05-03 SG SG2011080496A patent/SG175855A1/en unknown
- 2010-05-03 ES ES10771933.8T patent/ES2575100T3/es active Active
- 2010-05-03 EP EP10771933.8A patent/EP2427416B1/en active Active
- 2010-05-03 JP JP2012508861A patent/JP2012526052A/ja not_active Ceased
- 2010-05-03 MX MX2011011757A patent/MX2011011757A/es active IP Right Grant
-
2011
- 2011-10-27 IL IL216006A patent/IL216006A/en active IP Right Grant
- 2011-11-04 US US13/289,592 patent/US8927765B2/en active Active
-
2014
- 2014-11-12 JP JP2014229970A patent/JP5815829B2/ja not_active Expired - Fee Related
- 2014-12-08 US US14/563,523 patent/US9938221B2/en active Active
-
2018
- 2018-02-07 US US15/890,927 patent/US10815183B2/en not_active Expired - Fee Related
-
2020
- 2020-09-23 US US17/029,197 patent/US20210002202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015061852A5 (https=) | ||
| JP2012526052A5 (https=) | ||
| EA022445B1 (ru) | Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения | |
| JP2019187424A5 (https=) | ||
| JP2012509348A5 (https=) | ||
| JP2020512316A5 (https=) | ||
| HRP20230631T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| JP2017520613A5 (https=) | ||
| JP2018193382A5 (https=) | ||
| JP2016026151A5 (https=) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| NZ587955A (en) | Boron-containing small molecules as anti-inflammatory agents | |
| AR080792A1 (es) | Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias. | |
| JP2011513367A5 (https=) | ||
| WO2012162394A3 (en) | Compositions and methods for treating renal disease | |
| SI3004090T1 (en) | Chemical compounds | |
| JP2015063536A5 (https=) | ||
| JP2014519534A5 (https=) | ||
| JP2012020997A5 (https=) | ||
| JP2016512547A5 (https=) | ||
| JP2015501327A5 (https=) | ||
| JP2021513984A5 (https=) | ||
| MX2013013036A (es) | Polimero de acido maleico, eter de alilo y compuestos de acido (met) acrilico, y preparacion y uso de los mismos. | |
| JP2019531279A5 (https=) | ||
| HRP20241103T1 (hr) | 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba |